| Papers [1-15] of 100 :: [Page 1 of 7] | | Go to page : 1 2 3 4 5 6 7 —> | Search results on "GOVERNMENTS PHARMACEUTICAL COMPANIES": |
|
|
Governments and Pharmaceutical Companies, 2007.
This paper presents a research proposal to explore the effects of a long-term customer relationship in the pharmaceutical field.
2,017 words (approx. 8.1 pages), 21 sources, MLA, $ 63.95
»
Click here to show/hide summary
Abstract
The paper proposes to research the effects of applying long-term customer relationships in the pharmaceutical field, by targeting the cities in the Gulf areas and particularly, within the Kuwait market. The paper discusses the competition between the brand name industries and the generic industries and looks at how the governments of the Gulf countries are forced to choose between the two companies. The paper examines the mistrust that has developed because of the irresponsible situations and actions from both the pharmaceutical companies and the governments.
Outline:
Abstract
Introduction
The Research Problem
The Problem Statement
The Research Questions
Research Objectives
Methodology
Operational and Research Methodology
Problems and Limitations
From the Paper
"The pharmaceutical industry is a major business worldwide. The largest industry is the weapons industry and the pharmaceutical industry follows right behind the weapons industry. The pharmaceutical industry is the world's second largest business in terms of its products and services. Each year, governments from all over the world spend millions of dollars in order to secure medications, various equipment and other products and services that their countries need in order to help their sick citizens and maintain the health of those who are not sick. In addition to the government's spending on the medication and supplies from large suppliers, there is another competition from within in regards to outside research companies who produce different products that are used for the same ailments. These other research companies are known as the generic industry."
| |
|
Social Responsibility of Pharmaceutical Companies, 2004.
Study of the ethics of pharmaceutical companies when conducting business and promoting their products.
5,370 words (approx. 21.5 pages), 32 sources, MLA, $ 132.95
»
Click here to show/hide summary
Abstract
This paper addresses several questions concerning the ethical conduct of pharmaceutical companies. The paper considers whether doctors that sit on the boards of companies can be impartial when they make decisions to financially back research/drugs of the pharmaceutical company they represent, as well as what should be the corporate responsibility of the pharmaceutical companies. Also considered is whether pharmaceutical companies have systems in place to keep them ethically responsible and if advertising by pharmaceutical companies actually creates a demand for prescriptions when no need actually exists. Numerous graphs and tables are included.
From the Paper
"Indeed, one of the unique aspects of advertising prescription pharmaceuticals is the caveat ?Ask your doctor?. The consumer cannot go out and directly purchase the product (note that via the internet this is now possible), but traditionally must receive a physician?s endorsement by way of a prescription. The pharmaceutical industry uses this reasoning to defend its promotional tactics, claiming that because doctors ultimately authorize prescriptions the public is insulated from deceptive advertising. Yet research indicates that doctors are likely to prescribe drugs patients request under increasing pressure. Patients often insist on brand names over generic drugs, some of which are just as effective and less costly."
| |
|
International Finance and Pharmaceutical Company, 2008.
A case study analysis of the financial and operating performance, as well as market performance of the Company, a fictional pharmaceutical company.
1,822 words (approx. 7.3 pages), 2 sources, APA, $ 58.95
»
Click here to show/hide summary
Abstract
This paper presents a policy statement by the Company, a fictional pharmaceutical company, that discusses concerns and expectations about market conditions in the coming year, which may impact the Company's operations and profitability. It provides a plan that may impact upon future financial and operating performance for the Company. It also looks at threats to the financial stability of the Company.
Table of Contents:
Pounds, Dollar, and Euros: Purchasing Power Parity
US Economy Strength and Expansion of R&D Capacity
German Competitor Introduction of Generic Detervin
Federal Reserve Interest Rates
Inflation Rate in Turkey Expected to be Very High
Price Volatility on the New York Stock Exchange
Interest Rates on Government Bonds in US and Germany
Conclusion
From the Paper
"The Company faces several challenges in the coming financial years, including managing subsidiary operations in a volatile and changing environment. The fact that much of the growth potential for the Company is found in its foreign subsidiaries implies that it will have to find ways to finance operations through local avenues increasingly going forward. As the strength of the British pound become diluted closer to historical norms over time, the growth in subsidiaries should allow to the Company to increase both its operating and profit performance. Therefore, the coming year should represent significant opportunities to positively impact future growth with management's efforts to capitalize on market challenges around the world."
| |
|
Pharmaceutical Company and Industry Analysis, 2001.
A company analysis of Merck & Company, INC., a pharmaceutical company.
5,390 words (approx. 21.6 pages), 30 sources, $ 132.95
»
Click here to show/hide summary
Abstract
This paper analyzes pharmaceutical company, Merck & Company, INC., . The author provides a company profile and examines a number of issues such as: product marketing, service marketing, manufacturing, values and motives of the company.
From the Paper
"The pharmaceutical industry is one of the largest and most far reaching industries in our nation, and therefore is an industry that can neither be avoided nor ignored. The amount of money spent on healthcare is phenomenal ? representing 14 cents of every dollar of goods and services produced in the United States (Jhin, 1996). New drugs that emerged in the past decade proved to be extremely profitable, and with new advances in technology and faster drug approval rates, the outcome is clear ? more money plus better science equals more new drugs (Kleinke, 1998). "
| |
|
Pfizer Pharmaceutical Company, 2004.
An analysis of the marketing success of the Pfizer Pharmaceutical Company.
1,938 words (approx. 7.8 pages), 6 sources, MLA, $ 61.95
»
Click here to show/hide summary
Abstract
This paper examines how Pfizer is one of the most successful pharmaceutical companies in existence and how much, if not most, of Pfizer?s success is due to the corporation?s marketing genius, which is considered to be among the best in the industry. It looks at how Pfizer also has one of the best safety records in the industry, which helps in gaining investors and trust in the company. It also explores how, unlike most large corporations, Pfizer draws revenue from a limited number of products.
Outline
Company Structure and Marketing Strategies
Marketing Strengths
Threats
From the Paper
"The marketing principles utilized by Pfizer guides every aspect of the corporation?s business. There are five main principles that are fundamental to Pfizer?s business practices. First, the work conducted by Pfizer is grounded in science. With solid clinical research as a foundation, Pfizer?s marketing group uses its credibility and knowledge to develop important relationships within the medical community. Second, Pfizer takes an integrated approach to its marketing strategies. Innovation is promoted through the encouragement of teamwork within and across marketing groups. This also allows Pfizer to respond flexibly and promptly to changes in the market."
| |
|
The Walgreen's Pharmaceutical Company, 2002.
Analysis of a marketing strategy for Walgreen's Pharmaceutical Company.
1,900 words (approx. 7.6 pages), 6 sources, $ 71.95
»
Click here to show/hide summary
Abstract
This paper examines the strategic implementation of a marketing strategy for the Walgreen's Pharmaceutical Company. The author states clear objectives, and discusses products, promotion, services offered, price strategy, and methods of maintaining strategic competence.
| |
|
Wyeth Pharmaceuticals Company, 2008.
Describes the Wyeth Pharmaceuticals Company from the perspective of being an employee of the company.
1,845 words (approx. 7.4 pages), 12 sources, APA, $ 59.95
»
Click here to show/hide summary
Abstract
This paper presents an overview of the Wyeth Pharmaceuticals Company. The paper relates that Wyeth Pharmaceuticals is the globe's biggest pharmaceutical and healthcare company and that it holds the premier position among the 35 pharmaceutical companies present globally for patent based intellectual property. The paper also provides some additional statistics about Wyeth and then discusses the company's financial outcomes, state of competition and strengths. The paper concludes with a discussion on the process of product life cycle management at the company. Financial data about the Wyeth is also included with the paper.
Table of Contents:
Financial Outcomes
The Global Pharmaceutical Scenario and State of Competition
Wyeth's Product Strengths
Unique R&D - Our Core Strength
Learn & Confirm - A New Paradigm
Pharmaceuticals - A Knowledge Driven Industry
Product Life Cycle Management-A Sunrise Business Process for Pharmaceutical Industry
Financial Highlights
Selected Financial Data
Worldwide Net Revenue by Product
From the Paper
"In the sphere of consumer healthcare products, our company is a leader in research, development, production, and marketing of wide range of consumer healthcare products running in more than 65 nations. Our sales figures for the year 2006 have touched $2.5 billion, and Wyeth Consumer Healthcare is among the biggest OTC healthcare product in the entire world with workforce strength of 3200. The commitment of our company in improving the healthcare across the world has transformed Wyeth Consumer Healthcare into a top ranked competitor in excess of a dozen vital product categories inclusive of analgesic, cough cold allergy and vitamin/ nutritional supplements."
| |
|
Pharmaceutical Company Ethics: Profit Before People, 2001.
An examination of the ways in which the pharmaceutical industry manipulates the system, people and doctors in an effort to maximize their profits.
3,000 words (approx. 12.0 pages), 18 sources, MLA, $ 88.95
»
Click here to show/hide summary
Abstract
This paper takes an in depth look at the ways in which pharmaceutical companies unscrupulously put profit before people. Five of the main ways in which they do this that are discussed are; manipulation of research, undue influence over doctors prescribing practices, direct-to-consumer advertising, discrediting of their competitors pharmaceutical and natural alike, and investing only in profitable research. Each topic is discussed thoroughly with credible sources to back the data up.
From the Paper
"The pharmaceutical industry wants people to believe that their main goal is to help people. The Pharmaceutical Research and Manufacturers of America (PhRMA) has even begun airing feel-good commercials featuring people whose lives have been saved by medications. In reality, they spend billions of dollars every year to ensure their true purpose, maximum profit. Their influence begins in the research lab, where the sponsor, usually a pharmaceutical company with a huge financial stake in the findings, has more to say over how the study is conducted and what information is released then the actual investigators, leading some of the foremost medical journals in the world to fight back with strict guidelines. After the pharmaceutical companies get their products approved, they engage in a campaign of bribery to persuade doctors to prescribe their name brand, expensive drugs over their competitor's products. Not wanting to leave it up to the doctors alone to endorse their products, the pharmaceutical industry has started advertising directly to an unwitting populace, on television and in popular magazines. Pharmaceutical companies use their political power and vast economic resources to discredit and undermine non-drug treatment options for various diseases, particularly by attacking the burgeoning field of holistic medicine. Furthermore, the pharmaceutical companies have a long history of not investing in research that would lead to drugs for diseases that effect the world's poor, because there is little profit to be made in developing nations. Through various immoral practices, the pharmaceutical companies put profit ahead of the interests, health and safety of consumers. "
| |
|
Shire Pharmaceuticals - A Company Assessment, 2008.
A well-illustrated assessment of the company, Shire PLC, which has operations world wide.
3,535 words (approx. 14.1 pages), 28 sources, APA, $ 99.95
»
Click here to show/hide summary
Abstract
The paper is an in-depth, fully comprehensive study on the Shire Pharmaceutical Company, concentrating on the issues of finance and accounting. Performances of all sections of the company are highlighted and well-illustrated with graphs and tables, which are easy to analyze and understand. An interesting feature of the paper is a FAQ section which addresses issues, particularly relevant to financial management.
Outline:
Introduction
Methodology
Financial accounting
Financial m
Management accounting
From the Paper
"For the analysis of the literature gathered, one of the main objectives has to be able to present the analyses in a direct and concise manner, utilizing graphic representations or interpretations to illustrate deductions. Whenever possible, the research referred to expert opinions as the foundation of analyses as well as prevailing opinions posted through internet discussions about Shire, the pharmaceutical industry and trends in the FTSE. Models, summaries or tables derived from independent research were also used to facilitate discussion in the construction of the research as well as in the research documentation itself.
The consolidation of insights regarding Shire was done through a process of collaboration which then followed verification through a review of the primary and secondary literature used at the beginning of the research. The final written paper is designed to informative and comprehensive however there was recognition that the study could not be as exhaustive because of limitations on the length of the paper. This is one of the main challenges for the research: considering the amount of information the research required, significant discretion was to be exercised on what was to be included or excluded in the paper."
| |
|
The Government that Governs Best, 2004.
Asks the question: does the government that governs least govern the best?
1,338 words (approx. 5.4 pages), 2 sources, MLA, $ 44.95
»
Click here to show/hide summary
Abstract
There are many who believe that a true, freedom-loving democracy consists of a government that stays out of the business of its citizens as much as possible. This paper questions whether a government that does not govern much at all can really be an effective government. Even more importantly, it questions whether a government that does not govern much can protect and preserve the very democracy and freedom that created it in the first place. This paper looks at the writings of Alex de Tocqueville, specifically, his book, "Democracy in America", in order to determine if the government that governs least really is best.
From the Paper
"For most of the history of the United States, the idea that the government should not be very strong and should leave the people mainly to themselves has been a common theme of opinion among both the people and the politicians. It was certainly the common idea of the day when the Articles of Confederation were installed as our first constitution. The Articles of Confederation created a weak, loose league of friendship between the states, but established no real sort of federal government. The federal government it did create had no power beyond what the states gave it. As a result, nothing much ever got done, and the government and the states soon found out that the United States as a whole was not able to pay its bills, regulate its commerce, or ensure domestic tranquility."
| |
|
The Government and the Governed, 2004.
Compares and contrasts John Locke's and Jean Rousseau's theories about government and the people it governs.
2,700 words (approx. 10.8 pages), 3 sources, APA, $ 95.95
»
Click here to show/hide summary
Abstract
This paper examines the theories put forth by John Lock and Jean Jacques Rousseau concerning the ways that government and those governed should interact. The paper compares and contrasts both theories and examines their differing ideas on ways in which government must act to ensure a stable, orderly, just and prosperous society.
From the Paper
"Two philosophers who have contributed a great deal to an understanding of the relationship between citizens and government are Jean Jacques Rousseau and John Locke. The purpose of this report is to compare and contrast Rousseau's and Locke's theories regarding the ways in which the governed and the government must and should interact in order to ensure the continuation of a society that is stable, orderly and conducive to prosperity, equality and justice for its members. To that end ideas advanced..."
| |
|
The Pharmaceutical Industry, 2004.
This paper is a research proposal to investigate the impact of Structure-Conduct-Performance (SCP) of two multi-national pharmaceutical companies, Abbott Laboratories and Baxter Corporation, in their U.S., Canadian, and Brazilian markets.
2,365 words (approx. 9.5 pages), 4 sources, APA, $ 72.95
»
Click here to show/hide summary
Abstract
This paper delineates the objectives of the study: (1) To determine the impact of the environment in which the organization operates by using the PESTLE and SWOT (Strengths-Weaknesses-Opportunity-Threats) analysis methods;, (2) to present a brief history of the companies and to evaluate the products manufactured and sold; (3) to understand the health care market, the impact of laws and regulations and the role of national and local governments; (4) to perform a Michael Porter?s five-force analysis; and (5) to investigate the role of SCP. The author relates that this thesis will be based on a literature review and secondary data collection. The paper stresses that this study will provide useful information to policy and decision makers in the industry.
Table of Contents
Introduction
Proposed Methodology
Reflections and Potential Obstacles
Conclusion
From the Paper
"Competition is very intense in the modern day organization. Companies are increasingly striving to differentiate their products and services in the market in order to gain higher profits and a greater market share. Portfolio management, product life cycle management, decision analysis and risk analysis are becoming some of the strategies that have to be used by managers and executives all over the world. For-profit organizations are investing a lot of money and human resources to help identify variables that can make their organizations competitive in their respective markets. Failure in managing any one variable can result in the overall failure of the organization."
| |
|
Pharmaceutical Public Relations, 2005.
This paper examines the public relations practices of three pharmaceutical companies: Merck and its product VIOXX, Pfizer and its product Celebrex and Johnson & Johnson and its Direct-to-the-Consumer (DTC) marketing campaign.
3,000 words (approx. 12.0 pages), 9 sources, APA, $ 88.95
»
Click here to show/hide summary
Abstract
This paper explains that companies often encounter ethical issues and product problems, which open them to criticism and challenge; therefore, the way they handle the issue can help or hinder their public relations process and the image the public has of the company. The author points out that, in general, companies, which take responsibility quickly and work to get out all the facts, fare better than those that stonewall, which for many executives seems to be their first action as in the case of both Merck and its product VIOXX, Pfizer and its product Celebrex. The paper praises Johnson & Johnson's Direct-to-the-Consumer (DTC) marketing campaign because it shows concern for what concerns its customers and offering the consumer information to be used in making decisions; however, the same danger applies if a problem erupts, but the strategy fits well with current public attitudes and with business methods that burnish a company's image.
From the Paper
"Critics of Pfizer note not only that the company may have had information on the dangers long before the issue was revealed and did nothing but that the company advertised in a way that minimized any risks and so lulled the public into accepting the safety of the product:
Several of the medical experts convened last month by the Food and Drug Administration to review Vioxx, Pfizer Inc.'s Celebrex and related painkillers lashed out against advertising that minimized the risks of the medicines and led many patients to use them unnecessarily."
| |
|
The Pharmaceutical Industry, 2005.
This paper discusses the economics of the pharmaceutical industry.
3,130 words (approx. 12.5 pages), 7 sources, APA, $ 91.95
»
Click here to show/hide summary
Abstract
This paper explains that the intellectual property embodied in a drug is an extremely valuable asset for a pharmaceutical company, and its continued protection is directly related to the company's long-term success or failure. The author points out that Pfizer, the leading pharmaceutical company, has three main business practices and goals, which have overcome successfully the uncertainty in drug development and competitive pressures: (1) Extraordinary portfolio management practices, (2) security of daily management of resources and (3) profitable research and development. The paper relates that, in 1984 Congress passed of the Drug Price Competition and Patent Term Restoration Act, known as the Hatch-Waxman Act, which weakened patent law for pharmaceuticals making it easier for generic copies to enter the market.
Table of Contents
Intellectual Property
Risk and Resource Management
Drug Price Competition and Patent Term Restoration (Hatch-Waxman) Act
Food, Drug and Cosmetic Act
Amendments to the 1938 Food, Drug and Cosmetic Act
From the Paper
"As a result, a high average level of intellectual property protection is economically beneficial. The benefits of strong intellectual property protection are greater in the pharmaceutical industry than they are in other industries, because pharmaceutical firms rely more on patents to protect intellectual property than firms in other industries. When a drug becomes generic as the result of a lost patent, the price goes down, although the demand may remain the same. A less costly drug decreases profits for a pharmaceutical company, which in turn would use the additional profits to invest in their risk and development fund to search for new medicines and cures. Patent law gives pharmaceutical researchers the basic incentive to conduct research and discover new cures."
| |
|
Quality Management in the Pharmaceutical Industry, 2004.
Presents a literature review relating to the issue of total quality management (TQM) in the pharmaceutical industry.
2,267 words (approx. 9.1 pages), 17 sources, APA, $ 70.95
»
Click here to show/hide summary
Abstract
Good manufacturing practices (GMP) are considered part of the quality control system for companies producing pharmaceutical products. GMP principles aim to ensure the regular production for products that conform to the health standards required from regulatory bodies. GMP provides the general basics to determine the minimum acceptable requirements for the production at good products, covering all the activities related to the production process. This paper hypothesizes that, although ISO 9000 certification, which is the world-wide quality management and quality assurance standard, is not required for pharmaceutical companies, only those with a company culture mature and ethical enough to implement TQM successfully will be able to successfully implement GMP (industry-specific standard). There has been a great deal of confusion concerning whether being in compliance with the pharmaceutical GMP would successfully lead to obtaining ISO certification with minimum changes and costs, or whether achieving ISO certification is going to be a long and expensive road. This paper hypothesizes that the ultimate success of a company?s ISO program will not depend solely on how well-defined its quality system is, but rather its commitment to maintaining GMP.
From the Paper
"In general, this is mainly because the companies have not taken seriously enough the fact that TQM involves a cultural change for the organization. It creates a shift in power between boss and employee. Many managers, especially those who were inadequately trained, have seen employees as accessories to their jobs - as people to be told what to do. People who are disempowered often fail to take initiative in identifying process or sub-component faults. According to the laws of human nature, employees treated this way will leave a great deal of work to be handled by management. According to the theories of TQM, managers have to learn to support, encourage and listen."
|
|
|
